MedTrace Logo

Alcohol Cessation Intervention in an Acute Surgical Setting

NCT00986791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-03-30

No results posted yet for this study

Summary

Hazardous alcohol intake is an independent risk factor for postoperative complications after major and minor operations, elective and emergency procedures for men and women.

The aim of this study is to evaluate the effect of a 6-week Gold Standard Programme for alcohol cessation intervention in the perioperative period compared to the daily routine guidelines for patients with hazardous alcohol intake undergoing ankle fracture surgery.

Conditions

  • Acute Fracture Surgery
  • Alcohol Cessation Intervention
  • Postoperative Complications
  • Infection
  • Ankle Injuries

Interventions

OTHER

GSP-A

6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • Esbjerg Hospital - University Hospital of Southern Denmark

    collaborator OTHER

  • National Board of Health, Denmark

    collaborator OTHER_GOV

  • Karolinska Institutet

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Hanne Tønnesen, Professor · WHO-CC, Bispebjerg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2016-01-01
Completion
2018-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986791 on ClinicalTrials.gov